Table 2.
Examples of drug–polymer conjugates obtained by the SEDS processing
| Material | Carrier | Solvent | Purpose of delivery | References |
|---|---|---|---|---|
| 2,6-Dimethyl-8-(2-ethyl-6-methylbenzylamino)-3-hydroxymethylimidazo-[1,2-a]pyridine mesylate | Mannitol, Eudragit® E100 | Acetone, DMSO, MeOH | Bioavailability enhancement | 52 |
| 5-Aminosalicylic acid | Eudragit S100 | Acetone, DMSO | Controlled release | 68 |
| 5-Fluorouracil | PLA | DCM, EtOH | Controlled release | 91 |
| PLA, silica | DCM | 112 | ||
| PEG, PLA–PEG | Water, acetone, DCM | 113 | ||
| β-Carotene | PHBV | DCM | Controlled release | 108–110 |
| Albuterol sulfate | Lactose | MeOH | Inhalation powders | 80 |
| Amoxicillin | Chitosan | – | Bioavailability enhancement | 114 |
| Budesonide | γ-CD | EtOH | Bioavailability enhancement | 82, 115 |
| Celecoxib | PLGA | n-Butyl acetate, Water | Parenteral delivery | 28 |
| Cefuroxime axetil | HPMC 2910/PVP K-30 | DCM:EtOH (6:4 w/w) | Bioavailability enhancement | 116 |
| Curcumin | SF | HFIP | Bioavailability enhancement | 117, 118 |
| Hydrocortisone | PLGA, PLA, PCL | Acetone, chloroform, DCM, EA, isopropanol | Controlled release | 81 |
| Indomethacin | PLA, PLGA | DCM | Controlled release | 54 |
| PLA, Fe3O4 | DCM | Magnetically responsive delivery | 48 | |
| Lutein | Zein | Acetone, DMSO (7:3 v/v) | Controlled release | 119 |
| Lysozyme | PLA, PEG | DMSO:DCM (1:3 v/v) | Bioavailability enhancement | 94 |
| Methotrexate | SF, Fe3O4 | DCM, HFIP | Transdermal delivery | 120 |
| PLA–PEG–PLA | Acetone, DCM, DMSO | Controlled release | 29 | |
| Morphine | PLA–PEG–PLA | DCM, MeOH | Controlled release | 121 |
| PLA | DCM, EtOH, water | 58 | ||
| pDNA | Mannitol | Isopropanol | Inhalation powders | 122 |
| Paclitaxel | FA-PEG-PLA | DCM | Targeted delivery | 123 |
| PLA, PLGA | DCM | Controlled release | 73 | |
| Puerarin | PLA | DCM | Controlled release | 66 |
| DCM, EtOH | 74 | |||
| RNA | PLA–PEG, PLA | DCM | Transdermal controlled delivery | 124 |
| Salmeterol xinafoate | Lactose | Acetone, MeOH, THF | Inhalation powders | 78 |
| Silymarin | Phospholipids | DCM:EtOH (13:12 v/v) | Bioavailability enhancement | 125 |
Abbreviations: CD, cyclodextrin; DCM, dichloromethane; DMSO, dimethyl sulfoxide; EA, ethyl acetate; EtOH, ethanol; FA, folic acid; HFIP, 1,1,1,3,3,3-hexafluoro-2-propanol; HPMC, hydroxypropyl methylcellulose; MeOH, methanol; PCL, polycaprolactone; PEG, polyethylene glycol; PLA, polylactic acid; PHBV, poly(3-hydroxybutyrate-co-hydroxyvalerate); PLGA, poly(lactic-co-glycolic acid); PVP, polyvinylpyrrolidone; SEDS, solution-enhanced dispersion by supercritical fluids; SF, silk fibroin; THF, tetrahydrofuran; w/w, weight/weight; v/v, volume/volume.